IDEXX Laboratories Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
IDEXX Laboratories yıllık ortalama 13.1% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 13.2% annual. Gelirler growing yılda ortalama 9.8% oranında artmaktadır. IDEXX Laboratories'in özkaynak karlılığı 53.5% ve net marjı 22.5%'dir.
Anahtar bilgiler
13.1%
Kazanç büyüme oranı
13.9%
EPS büyüme oranı
Medical Equipment Sektör Büyümesi | 8.9% |
Gelir büyüme oranı | 9.8% |
Özkaynak getirisi | 53.5% |
Net Marj | 22.5% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Gelir ve Gider Dağılımı
IDEXX Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 3,845 | 866 | 947 | 214 |
30 Jun 24 | 3,785 | 846 | 934 | 208 |
31 Mar 24 | 3,725 | 867 | 925 | 199 |
31 Dec 23 | 3,661 | 845 | 902 | 191 |
30 Sep 23 | 3,588 | 823 | 888 | 183 |
30 Jun 23 | 3,514 | 791 | 877 | 183 |
31 Mar 23 | 3,431 | 699 | 858 | 259 |
31 Dec 22 | 3,367 | 679 | 851 | 255 |
30 Sep 22 | 3,340 | 670 | 848 | 257 |
30 Jun 22 | 3,309 | 664 | 840 | 249 |
31 Mar 22 | 3,274 | 735 | 821 | 164 |
31 Dec 21 | 3,215 | 745 | 796 | 161 |
30 Sep 21 | 3,135 | 757 | 770 | 154 |
30 Jun 21 | 3,047 | 728 | 777 | 152 |
31 Mar 21 | 2,858 | 674 | 739 | 146 |
31 Dec 20 | 2,707 | 582 | 735 | 141 |
30 Sep 20 | 2,591 | 497 | 717 | 138 |
30 Jun 20 | 2,475 | 460 | 674 | 134 |
31 Mar 20 | 2,457 | 437 | 681 | 135 |
31 Dec 19 | 2,407 | 428 | 669 | 133 |
30 Sep 19 | 2,351 | 423 | 657 | 128 |
30 Jun 19 | 2,291 | 407 | 642 | 123 |
31 Mar 19 | 2,252 | 390 | 638 | 120 |
31 Dec 18 | 2,213 | 377 | 632 | 118 |
30 Sep 18 | 2,170 | 330 | 621 | 117 |
30 Jun 18 | 2,117 | 307 | 610 | 115 |
31 Mar 18 | 2,045 | 284 | 596 | 112 |
31 Dec 17 | 1,969 | 263 | 575 | 109 |
30 Sep 17 | 1,906 | 277 | 561 | 106 |
30 Jun 17 | 1,862 | 263 | 547 | 104 |
31 Mar 17 | 1,820 | 245 | 534 | 102 |
31 Dec 16 | 1,775 | 222 | 522 | 101 |
30 Sep 16 | 1,732 | 214 | 516 | 101 |
30 Jun 16 | 1,690 | 202 | 502 | 100 |
31 Mar 16 | 1,637 | 192 | 493 | 99 |
31 Dec 15 | 1,602 | 192 | 482 | 100 |
30 Sep 15 | 1,554 | 174 | 475 | 99 |
30 Jun 15 | 1,531 | 182 | 467 | 99 |
31 Mar 15 | 1,508 | 182 | 457 | 100 |
31 Dec 14 | 1,486 | 182 | 448 | 98 |
30 Sep 14 | 1,488 | 199 | 435 | 96 |
30 Jun 14 | 1,443 | 193 | 422 | 93 |
31 Mar 14 | 1,405 | 190 | 409 | 89 |
31 Dec 13 | 1,377 | 188 | 401 | 88 |
Kaliteli Kazançlar: IDXX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: IDXX 'nin mevcut net kar marjları (22.5%) geçen yılın (22.9%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IDXX şirketinin kazancı son 5 yılda yılda 13.1% oranında arttı.
Büyüme Hızlandırma: IDXX 'un son bir yıldaki kazanç büyümesi ( 5.3% ) 5 yıllık ortalamasının ( 13.1% /yıl) altındadır.
Kazançlar vs. Sektör: IDXX geçen yılki kazanç büyümesi ( 5.3% ) Medical Equipment sektörünün 11.7% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: IDXX 'nin Özsermaye Getirisi ( 53.5% ) ödenmemiş olarak değerlendirilmektedir.